ADMA Biologics Inc vs Autodesk Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Autodesk Inc trades at $248.05 (market cap $54.07B). The key difference: Autodesk Inc is far larger — about 24.8× ADMA Biologics Inc's market cap, and Autodesk Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ADSK | |
|---|---|---|
Market Cap | $2.18B | $54.07B |
Sector | Health | Technology |
52-Week High | $20.38 | $326.79 |
52-Week Low | $7.60 | $187.72 |
Enterprise Value | $2.25B | $53.87B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
No Aura AI signal available yet.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →